Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kitakyushu-shi
Clinical trial register · Japan

Clinical Trials in Kitakyushu-shi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Bristol-Myers Squibb7 AstraZeneca7 Biogen5 Pfizer4 AbbVie4
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kitakyushu-shi

56 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
AstraZeneca
Phase 3
500
Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito
2026-08-24
Recruiting
Pfizer
Phase 3
336
Kitakyushu-shi, Niigata
2026-07-30
Recruiting
Alkermes, Inc.
Phase 3
176
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-ku, Kumamoto, Tokyo
2026-04-22
Recruiting
Alkermes, Inc.
Phase 3
150
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-Ku, Kumamoto
2026-04-06
Recruiting
Sanofi
Observational
2,500
Kitakyushu-Shi, Takamatsu, Saga
2026-04-01
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Nagoya, Chiba, Kitakyushu-shi, Fukushima, Asahikawa-shi, Sapporo, Kobe, Kanazawa
2026-03-10
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
75
Ibaraki, Kitakyushu-shi, Kumamoto
2026-03-04
Recruiting
Eli Lilly and Company
Phase 3
900
Chiba, Chūōku, Kitakyushu-Shi, Miyazaki, Nagareyama, Ōita, Saitama, Sashima
2026-02-09
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Fuchū, Kagoshima, Kitakyushu-shi, Osaka, Sanuki, Shimonoseki
2026-01-15
Recruiting
Shionogi
Phase 2
192
Kasugai-Shi, Nagoya-Shi Nakamura-Ku, Chikushino-shi, Fukuoka, Fukuoka-Shi Chuo-Ku, Fukuoka-Shi Hakata-Ku, Kitakyushu-Shi Yahatanishi-Ku, Kitakyushu-Shi
2025-12-11
Recruiting
Pfizer
Phase 3
32,500
Nagoya, Iizuka-shi, Itoshima, Kitakyushu-shi, Onga-gun, Koga, Kumamoto, Ōmura
2025-12-10
Recruiting
Takeda
Phase 3
110
Nagoya, Kitakyushu-shi, Tsu, Mie, Osaka, Itabashi-Ku
2025-12-04
Recruiting
Daiichi Sankyo
Phase 3
686
Hidaka-shi, Hirakata-shi, Hirosaki-shi, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kumamoto, Kurume-shi
2025-10-24
Recruiting
Bristol-Myers Squibb
Phase 3
424
Toyoake, Ichikawa, Iizuka, Kitakyushu-shi, Sapporo, Yokohama, Karatsu, Bunkyo-ku
2025-10-08
Recruiting
Bristol-Myers Squibb
Observational
223
Sendai, Toyama, Kitakyushu-Shi, Wakayama
2025-10-08
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Sapporo, Himeji-shi, Takarazuka-shi, Kanazawa
2025-06-25
Recruiting
GlaxoSmithKline
Phase 3
981
Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki
2025-06-20
Recruiting
Biogen
Phase 3
454
Toyoake-shi, Hirosaki-shi, Chiba, Urayasu-Shi, Sapporo, Kitakyushu-shi, Fukushima, Kawasaki-shi
2025-05-08
Recruiting
AstraZeneca
Phase 1
72
Bunkyō City, Kita-gun, Kitakyushu-shi, Kyoto, Nagasaki
2025-05-01
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Chiba, Chūōku, Hirakata, Hyōgo, Kitakyushu-shi, Nagoya, Osaka, Ōita
2025-01-09
Active, closed
AbbVie
Phase 3
99
Nagoya, Toyoake, Matsudo-Shi, Fukuoka, Kasuga-shi, Kitakyushu-shi, Maebashi, Sapporo
2024-12-22
Active, closed
Genmab
Phase 3
191
Matsuyama, Kitakyushu-shi, Hiroshima, Kobe, Kumamoto, Osakasayama-shi, Bunkyō City, Chūōku
2024-11-25
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Nagoya, Kitakyushu-shi, Naha, Kita-ku, Bunkyō City
2024-09-17
Active, closed
Pfizer
Observational
450
Kitakyushu-shi, Kurume-shi, Ebina, Sendai, Niigata, Osaka, Hamamatsu, Bunkyo-ku
2024-08-07
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
20
Nagoya, Akita, Urayasu-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Fukushima, Gifu
2024-05-17
Recruiting
CSL Behring
Phase 2/3
3,110
Ichinomiya-shi, Urayasu-shi, Kitakyushu-shi, Maebashi, Sapporo, Kusatsu-shi, Shinjuku-Ku, Hashima-gun
2024-04-27
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Bunkyō City, Chiba, Fukuoka, Kamakura, Kasugai-shi, Kitakyushu-shi, Kobe, Matsumoto-shi
2024-03-29
Active, closed
AbbVie
Phase 2
156
Gamagori-shi, Nagakute, Kashiwa-shi, Urayasu-shi, Kitakyushu-shi, Fukushima, Gifu, Ogaki-shi
2024-03-23
Active, closed
Janssen Pharmaceutical K.K.
Phase 3
19
Hokkaido, Ichinomiya, Itabashi Ku, Kitakyushu-shi, Kumamoto, Nagoya, Osaka, Sendai
2024-02-09
Active, closed
Bristol-Myers Squibb
Phase 1/2
83
Anjo-shi, Nagoya, Toyohashi, Kamogawa, Kashiwa, Narita, Iizuka, Kitakyushu-shi
2023-11-20
Recruiting
Amgen
Phase 3
750
Nagoya, Hirosaki-shi, Chiba, Kashiwa-shi, Matsuyama, Toon-shi, Fukuoka, Kitakyushu-shi
2023-11-16
Active, closed
AstraZeneca
Phase 3
863
Amagasaki-shi, Hakodate-shi, Hiroshima, Kitaadachi-gun, Kitakyushu-shi, Matsuyama, Nagoya, Nishinomiya-shi
2023-11-09
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Itabashi Ku, Kitakyushu-shi, Mito, Nagoya, Osaka Sayama Shi, Sendai, Shinjuku, Tsu
2023-10-12
By invitation
Biogen
Phase 3
306
Nagoya, Yoshida-gun, Kitakyushu-shi, Kakogawa-shi, Kanazawa, Kawasaki-shi, Yokohama, Kumamoto
2023-10-03
Active, closed
Bristol-Myers Squibb
Phase 3
774
Nagoya, Toyoake-shi, Kitakyushu-shi, Sapporo, Nishinomiya-shi, Tsukuba, Kahoku-gun, Kanazawa
2023-09-11
Active, closed
AbbVie
Phase 3
1,014
Kitakyushu-shi, Sapporo, Sendai, Miyazaki, Okayama, Naha, Kawagoe, Bunkyo-ku
2023-07-25
Active, closed
Incyte Corporation
Phase 2
247
Chūōku, Fukuoka, Kishiwada, Kitakyushu-shi, Mizunami-shi, Osaka, Sakaide-shi, Sapporo
2023-07-11
Recruiting
Pfizer
Phase 3
318
Kitakyushu-shi, Kawasaki, Sendai, Okayama, Ōtsu, Bunkyo-ku, Shinjuku-ku, Ube
2023-05-20
Active, closed
TRISCEND JAPAN Study
NCT05760989Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
45
Kitakyushu-shi, Isehara-shi, Sendai, Osaka, Suita, Suita-shi, Shinjuku-Ku
2023-02-06
Active, closed
Bristol-Myers Squibb
Phase 3
606
Nagoya, Kashiwa, Kitakyushu-shi, Sapporo, Higashiibaraki, Kanazawa, Shiwa-gun Yahaba-cho, Kamakura
2023-01-10
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Kitakyushu-shi, Sapporo, Amagasaki, Sagamihara, Sendai, Shinagawa-ku, Osaka
2022-12-14
Recruiting
Celgene
Phase 3
810
Kashiwa, Kitakyushu-shi, Sapporo, Higashiibaraki, Shiwa-gun Yahaba-cho, Kamakura, Iruma, Koshigaya
2022-09-20
Active, closed
Biogen
Phase 2/3
450
Nagoya, Toyoake-shi, Aomori, Urayasu-shi, Yoshida-gun, Kitakyushu-shi, Sapporo, Kakogawa-shi
2022-09-13
By invitation
Biogen
Phase 3
864
Nagoya, Toyoake-shi, Chiba, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo, Himeji-shi
2022-06-10
Recruiting
AbbVie
Phase 3
768
Nagoya, Hirosaki-shi, Kashiwa-shi, Fukuoka, Kitakyushu-shi, Kurume-shi, Ota-shi, Fukuyama
2022-03-25
Active, closed
AstraZeneca
Phase 3
363
Bunkyō City, Chiba, Hiroshima, Kita-gun, Kitakyushu-shi, Matsumoto-shi, Nagasaki, Okayama
2022-02-15
Active, closed
UCB Biopharma SRL
Phase 3
113
Chiba, Isehara, Kitakyushu-shi, Kodaira, Koriyama-shi, Sendai, Shinjuku-ku, Suita-shi
2022-02-02
Active, closed
Biogen
Phase 3
562
Nagoya, Toyoake-shi, Chiba, Narashino-shi, Fukuoka, Kitakyushu-shi, Hiroshima, Sapporo
2021-07-16
Active, closed
AstraZeneca
Phase 3
367
Chiba, Chūōku, Hamamatsu, Hiroshima, Itabashi-ku, Kita-gun, Kitakyushu-shi, Meguro-ku
2021-06-08
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Nagoya, Kitakyushu-shi, Kawasaki-shi, Kashihara-Shi, Shinjuku-ku, Suginami-ku
2021-02-23
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Chiba, Kitakyushu-shi, Shiwa-gun, Chiyoda-ku, Okamoto, Okayama, Tokyo, Toyama
2020-10-15
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
Nagoya, Kitakyushu, Sendai, Miyazaki, Mitaka, Shinjuku, tabashi City, Kitakyushu-shi
2020-07-01
Active, closed
Bristol-Myers Squibb
Phase 3
461
Nagoya, Kashiwa-shi, Kitakyushu-shi, Hiroshima, Kobe, Kanazawa, Yokohama, Sendai
2019-11-05
Active, closed
AstraZeneca
Phase 3
825
Habikino-shi, Himeji-shi, Hiroshima, Iwakuni-shi, Kitaadachi-gun, Kitakyushu-shi, Kurashiki Shi, Nagoya
2018-12-06
Active, closed
AstraZeneca
Phase 3
682
Bunkyō City, Fukuoka, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kitakyushu-shi, Kobe
2015-10-21
Rows per page Showing 1–56 of 56
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kitakyushu-shi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 56 of those studies with a site in Kitakyushu-shi.

How many clinical trials are recruiting in Kitakyushu-shi?

25 of the 56 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 29 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kitakyushu-shi), 56 studies
PhaseStudiesRecruitingShare
Phase 3391869.6%
Phase 2528.9%
Observational325.4%
Phase 2/3315.4%
Not applicable203.6%
Phase 1213.6%
Phase 1/2101.8%
Phase 4111.8%

Most active sponsors

Lead sponsors with the most studies (Kitakyushu-shi)
Lead sponsorStudiesRecruiting
AstraZeneca72
Bristol-Myers Squibb72
Biogen51
AbbVie41
Pfizer43
Janssen Research & Development, LLC32
Alexion Pharmaceuticals, Inc.21
Alkermes, Inc.22
Amgen22
Incyte Corporation20
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.